On Aug 14, 2019, the US Food and Drug Administration (FDA) approved the drug pretomanid to be used in combination with bedaquiline and linezolid to treat drug-resistant tuberculosis. Developed by the non-profit organisation, , pretomanid has been shown to increase treatment success in multidrug-resistant and extensively drug-resistant tuberculosis.

中文翻译：

---

耐药结核病治疗取得突破。

2019年8月14日，美国食品药品监督管理局（FDA）批准了前驱体类药物与贝达喹啉和利奈唑胺合用，用于治疗耐药性结核病。由非营利组织开发的前驱体已被证明可以提高耐多药和广泛耐药性结核病的治疗成功率。